Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
March 23, 2022 05:30 PM EDTUpdated March 25, 09:22 AM
Pharma
FDA+

No­var­tis' ra­dio­phar­ma drug wins ap­proval in tough-to-treat prostate can­cer pa­tients

Max Gelman

Senior Editor

One of the key ways in which No­var­tis CEO Vas Narasimhan hopes to stave off gener­ic com­pe­ti­tion took a gi­ant leap for­ward Wednes­day af­ter­noon. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times